A system (30) and method for detecting or predicting toxicity induced by radiation therapy. A device (34) is configured for determining polypeptide biomarkers present in a urine sample. At least one processor (36) is programmed to detect or predict radiation toxicity based on one or more polypeptide biomarkers determined to be in the urine sample.

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.

Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.

The present disclosure relates to methods of identifying components present in intact lipoprotein particles. Methods provided include single particle mass spectrometry, such as charge detection mass spectrometry (CDMS). Distinct subtypes and subpopulations that exist within lipoprotein density classes are determined based on simultaneously measured m/z and charge of ionized lipoprotein particles.

The invention provides methods of diagnosing autism spectrum disorders (ASD) by analyzing ratios of concentrations of selected amine containing compounds in a sample, such as a blood sample, from a subject. Based on the discovery that specific amine containing compounds and their ratios are dysregulated in patients with ASD, these metabotypes or subtypes of metabolism have the potential to diagnose earlier and suggest more precise treatment based on the metabolism of the individual. The invention provides methods of analyzing amine containing compounds and ratios in a test subject and determining whether the test subject has or is at risk of developing an ASD by comparing ratios from the test subject to ratios from subjects diagnosed with a neurodevelopmental disorder such as ASD who share a common profile of metabolism which is not found in the majority of typically developing subjects. The invention also provides methods of determining a course of treatment for an individual that has or is at risk of developing an ASD based on the individuals metabotype.

Methods for quantitation of fC1-INH from dried blood spot are provided herein. Such methods may comprise spotting and drying a blood sample on a support member, extracting protein from the dried blood sample and measuring the level of fC1-INH in the extracted proteins.

A method for rapid, high throughput screening of the activities of enzymes, especially ligninases and its enzyme cocktails, using nanostructure initiator mass spectrometry (NIMS) surfaces, substrates and methodology.

Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.

This document relates to methods for detecting and quantifying heavy and light chains of immunoglobulin using mass spectrometry techniques.

The present invention is directed to methods of treating Alzheimer's disease. Also disclosed are methods of identifying novel compounds that may be useful in the treatment and prevention of Alzheimer's disease as well as methods of determining the Alzheimer's disease status of a subject.